AB Science S.A. (0Q77.L)
EUR 0.87
(-6.75%)
EUR 0.87
(-6.75%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -10.04 Million EUR | 26.2% |
| 2022 | -13.61 Million EUR | 5.86% |
| 2021 | -14.46 Million EUR | 3.87% |
| 2020 | -15.04 Million EUR | 30.82% |
| 2019 | -21.74 Million EUR | 16.55% |
| 2018 | -26.06 Million EUR | 3.91% |
| 2017 | -27.12 Million EUR | 2.07% |
| 2016 | -27.69 Million EUR | -3.67% |
| 2015 | -26.71 Million EUR | -65.81% |
| 2014 | -16.11 Million EUR | -10.27% |
| 2013 | -14.61 Million EUR | -33.01% |
| 2012 | -10.98 Million EUR | -13.82% |
| 2011 | -9.65 Million EUR | -1.71% |
| 2010 | -9.48 Million EUR | -17.0% |
| 2009 | -8.11 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -4.46 Million EUR | 0.0% |
| 2023 Q3 | -787 Thousand EUR | 92.44% |
| 2023 Q4 | -787 Thousand EUR | 0.0% |
| 2023 FY | -10.04 Million EUR | 26.2% |
| 2023 Q1 | -5.2 Million EUR | 19.59% |
| 2023 Q2 | -10.41 Million EUR | -100.0% |
| 2022 Q3 | -3.23 Million EUR | 54.67% |
| 2022 Q2 | -7.14 Million EUR | -100.0% |
| 2022 Q1 | -3.57 Million EUR | 63.6% |
| 2022 FY | -13.61 Million EUR | 5.86% |
| 2022 Q4 | -6.47 Million EUR | -100.0% |
| 2021 Q2 | -4.65 Million EUR | -100.0% |
| 2021 Q1 | -2.32 Million EUR | 62.72% |
| 2021 FY | -14.46 Million EUR | 3.87% |
| 2021 Q4 | -9.8 Million EUR | -100.0% |
| 2021 Q3 | -4.9 Million EUR | -5.35% |
| 2020 Q2 | -8.8 Million EUR | -100.0% |
| 2020 Q3 | -3.12 Million EUR | 64.53% |
| 2020 FY | -15.04 Million EUR | 30.82% |
| 2020 Q1 | -4.4 Million EUR | 49.6% |
| 2020 Q4 | -6.24 Million EUR | -100.0% |
| 2019 Q2 | -13.01 Million EUR | -100.0% |
| 2019 FY | -21.74 Million EUR | 16.55% |
| 2019 Q1 | -6.5 Million EUR | 12.88% |
| 2019 Q4 | -8.73 Million EUR | -100.0% |
| 2019 Q3 | -4.36 Million EUR | 66.46% |
| 2018 Q2 | -5.56 Million EUR | 0.0% |
| 2018 Q1 | -5.56 Million EUR | 18.29% |
| 2018 FY | -26.06 Million EUR | 3.91% |
| 2018 Q4 | -7.47 Million EUR | 0.0% |
| 2018 Q3 | -7.47 Million EUR | -34.34% |
| 2017 FY | -27.12 Million EUR | 2.07% |
| 2017 Q4 | -6.8 Million EUR | 0.0% |
| 2017 Q1 | -6.75 Million EUR | -4.38% |
| 2017 Q2 | -6.75 Million EUR | 0.0% |
| 2017 Q3 | -6.8 Million EUR | -0.74% |
| 2016 Q4 | -6.47 Million EUR | 0.0% |
| 2016 Q3 | -6.47 Million EUR | 12.26% |
| 2016 Q1 | -7.37 Million EUR | -7.38% |
| 2016 FY | -27.69 Million EUR | -3.67% |
| 2016 Q2 | -7.37 Million EUR | 0.0% |
| 2015 FY | -26.71 Million EUR | -65.81% |
| 2015 Q2 | -6.48 Million EUR | 0.0% |
| 2015 Q4 | -6.86 Million EUR | 0.0% |
| 2015 Q3 | -6.86 Million EUR | -5.86% |
| 2015 Q1 | -6.48 Million EUR | -45.75% |
| 2014 Q4 | -4.45 Million EUR | 0.0% |
| 2014 FY | -16.11 Million EUR | -10.27% |
| 2014 Q1 | -3.6 Million EUR | 12.76% |
| 2014 Q2 | -3.6 Million EUR | 0.0% |
| 2014 Q3 | -4.45 Million EUR | -23.53% |
| 2013 Q2 | -3.17 Million EUR | 0.0% |
| 2013 Q3 | -4.13 Million EUR | -30.13% |
| 2013 Q4 | -4.13 Million EUR | 0.0% |
| 2013 FY | -14.61 Million EUR | -33.01% |
| 2013 Q1 | -3.17 Million EUR | 0.0% |
| 2012 FY | -10.98 Million EUR | -13.82% |
| 2011 FY | -9.65 Million EUR | -1.71% |
| 2010 FY | -9.48 Million EUR | -17.0% |
| 2009 FY | -8.11 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Boiron SA | 35.82 Million EUR | 128.046% |
| Laboratorios Farmaceuticos Rovi, S.A. | 170.33 Million EUR | 105.899% |
| Vetoquinol SA | 55.56 Million EUR | 118.085% |
| Valneva SE | -101.42 Million EUR | 90.094% |
| Nanobiotix S.A. | -39.7 Million EUR | 74.69% |
| PHAXIAM Therapeutics S.A. | -23.48 Million EUR | 57.221% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | 64.547% |
| BioSenic S.A. | -28.77 Million EUR | 65.084% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 93.199% |
| Formycon AG | 75.79 Million EUR | 113.257% |